As Bristol-Myers Squibb’s HIV drugs Reyataz and Sustiva lose patent protection, the company plans to lay off 58 staffers in October 2017.
AbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.
Amgen announced that the U.S. FDA approved the supplemental Biologics License Application for Vectibix (panitumumab) for patients with wild-type RAS metastatic colorectal cancer.
Array BioPharma and Bristol-Myers Squibb announced the companies have entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Array’s investigational MEK inhibitor binimetinib in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment for metastatic colorectal cancer in patients with microsatellite stable tumors.
Array BioPharma entered into a clinical trial collaboration with Merck to study a novel drug combo for colorectal cancer patients with microsatellite stable tumors.
The U.S. Food and Drug Administration said it approved Bayer AG’s drug Stivarga to treat liver cancer, the first such approval in nearly a decade.
Chi-Med’s fruquintinib met all main endpoints in a Phase III trial as a third-line treatment in patients with locally advanced or metastatic colorectal cancer.
German drugmaker Bayer said it submitted an application to have its cancer drug Regorafenib approved for the second-line treatment of liver cancer patients following successful clinical trials.
Bristol-Myers Squibb will evaluate the use of its blockbuster immunotherapy Opdivo with an experimental drug from Nektar Therapeutics to treat multiple cancers.